151 related articles for article (PubMed ID: 33754183)
1. S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults.
Tran L; Nikanjam M; Capparelli EV; Bertino JS; Nafziger AN; Kashuba ADM; Turpault S; Ma JD
Eur J Clin Pharmacol; 2021 Sep; 77(9):1349-1356. PubMed ID: 33754183
[TBL] [Abstract][Full Text] [Related]
2. S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction.
Chang AT; Bertino JS; Nafziger AN; Kashuba AD; Turpault S; Lewis LD; Ma JD
Ther Drug Monit; 2016 Jun; 38(3):383-7. PubMed ID: 26818625
[TBL] [Abstract][Full Text] [Related]
3. Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults.
Yang J; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Stoch SA; Bertino JS; Nafziger AN; Ma JD
J Clin Pharmacol; 2019 Nov; 59(11):1495-1504. PubMed ID: 31051051
[TBL] [Abstract][Full Text] [Related]
4. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
[TBL] [Abstract][Full Text] [Related]
5. Fexofenadine Plasma Concentrations to Estimate Systemic Exposure in Healthy Adults Using a Limited Sampling Strategy with a Population Pharmacokinetic Approach.
Piscitelli J; Nikanjam M; Capparelli EV; Blaquera CL; Penzak SR; Nolin TD; Paine MF; Ma JD
Ther Drug Monit; 2023 Aug; 45(4):539-545. PubMed ID: 36645711
[TBL] [Abstract][Full Text] [Related]
6. Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach.
Yang J; Patel M; Nikanjam M; Capparelli EV; Tsunoda SM; Greenberg HE; Penzak SR; Aubrey Stoch S; Bertino JS; Nafziger AN; Ma JD
J Clin Pharmacol; 2018 Sep; 58(9):1205-1213. PubMed ID: 29663428
[TBL] [Abstract][Full Text] [Related]
7. Limitations of S-warfarin truncated area under the concentration-time curve to predict cytochrome P450 2c9 activity.
Wu JC; Nafziger AN; Bertino JS; Ma JD
Drug Metab Lett; 2012 Jun; 6(2):94-101. PubMed ID: 22594566
[TBL] [Abstract][Full Text] [Related]
8. A physiologically-based pharmacokinetic/pharmacodynamic modeling approach for drug-drug-gene interaction evaluation of S-warfarin with fluconazole.
Geng K; Shen C; Wang X; Wang X; Shao W; Wang W; Chen T; Sun H; Xie H
CPT Pharmacometrics Syst Pharmacol; 2024 May; 13(5):853-869. PubMed ID: 38487942
[TBL] [Abstract][Full Text] [Related]
9. Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers.
Ma JD; Nafziger AN; Kashuba AD; Kim MJ; Gaedigk A; Rowland E; Kim JS; Bertino JS
J Clin Pharmacol; 2004 Jun; 44(6):570-6. PubMed ID: 15145963
[TBL] [Abstract][Full Text] [Related]
10. Limitations of fexofenadine limited sampling strategy using plasma concentrations and partial area under the concentration-time curve to estimate transporter activity in healthy adults.
Liyanage M; Blaquera CL; Piscitelli J; Penzak SR; Nolin TD; Paine MF; Ma JD
Int J Clin Pharmacol Ther; 2023 Jun; 61(6):262-269. PubMed ID: 37042268
[TBL] [Abstract][Full Text] [Related]
11. A Physiological-Based Pharmacokinetic Model Embedded with a Target-Mediated Drug Disposition Mechanism Can Characterize Single-Dose Warfarin Pharmacokinetic Profiles in Subjects with Various
Cheng S; Flora DR; Rettie AE; Brundage RC; Tracy TS
Drug Metab Dispos; 2023 Feb; 51(2):257-267. PubMed ID: 36379708
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
Turpault S; Brian W; Van Horn R; Santoni A; Poitiers F; Donazzolo Y; Boulenc X
Br J Clin Pharmacol; 2009 Dec; 68(6):928-35. PubMed ID: 20002088
[TBL] [Abstract][Full Text] [Related]
13. CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites.
Flora DR; Rettie AE; Brundage RC; Tracy TS
J Clin Pharmacol; 2017 Mar; 57(3):382-393. PubMed ID: 27539372
[TBL] [Abstract][Full Text] [Related]
14. Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure.
Castellan AC; Tod M; Gueyffier F; Audars M; Cambriels F; Kassaï B; Nony P;
Clin Pharmacokinet; 2013 Mar; 52(3):199-209. PubMed ID: 23344982
[TBL] [Abstract][Full Text] [Related]
15. A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.
Morcos PN; Chang L; Kulkarni R; Giraudon M; Shulman N; Brennan BJ; Smith PF; Tran JQ
Eur J Clin Pharmacol; 2013 Nov; 69(11):1939-49. PubMed ID: 23872824
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis.
Zhang J; Tian L; Huang J; Huang S; Chai T; Shen J
Cardiovasc Ther; 2017 Feb; 35(1):26-32. PubMed ID: 27661060
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates.
Sathe AG; Othman AA; Mohamed MF
J Clin Pharmacol; 2021 Mar; 61(3):307-318. PubMed ID: 32960975
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping.
Tai W; Gong SL; Tsunoda SM; Greenberg HE; Gorski JC; Penzak SR; Stoch SA; Ma JD
Drug Metabol Drug Interact; 2013; 28(4):217-23. PubMed ID: 24114901
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug-drug interaction studies for CYP2C9.
Klein K; Gueorguieva I; Aarons L
J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):147-60. PubMed ID: 22270321
[TBL] [Abstract][Full Text] [Related]
20. Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance.
Shaul C; Blotnick S; Adar L; Muszkat M; Bialer M; Caraco Y
Clin Pharmacokinet; 2022 Aug; 61(8):1187-1198. PubMed ID: 35699912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]